CURRENT RECRUITING TRIALS
CONTACT US AT als-cru.neuro@mcgill.ca
CALL (514) 514-398-6183
COMBAT-ALS (ibudilast)
From clinicaltrials.gov:
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
ION363-CS1 (FUS-ALS)
A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis patients with Fused in Sarcoma mutations (FUS-ALS)
To evaluate the clinical efficacy of ION363 in clinical functioning and survival in Amyotrophic Lateral Sclerosis (ALS) patients with Fused in Sarcomamutations (FUS-ALS).
EMBODIED MINDFULNESS
QURALIS QRC-201
A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in ALS
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
OBSERVATIONAL STUDIES
CAPTURE ALS
The Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
This is a prospective, multicenter, longitudinal cohort study investigating the natural history of ALS and related disorders. CAPTURE ALS will collect data and biosamples from participants to create the most comprehensive biological picture of people living with ALS. Through open science, this information collected from participants will be shared anonymously with worldwide ALS researchers to better understand and treat ALS.
For this study, male and female patients and healthy controls aged 18 or older will be recruited at 4 sites across Canada. Patients with ALS or a related disorder including ALS-Frontotemporal Dementia, Primary Lateral Sclerosis and Progressive Muscular Atrophy, or asymptomatic individuals with a known ALS mutation are eligible to participate.
CALS-NIC2 (Biomarkers)
Novel MRI Biomarkers for monitoring disease progression in ALS
From clinicaltrials.gov:
Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a “biomarker”) by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS.
Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 – 3 hours. MRI is a safe technique that does not involve radiation.
REFINE-ALS
Radicava®/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
The purpose of this study is to find biomarkers that show why edaravone is slowing ALS symptom progression. The data gathered during the study may also be useful for medical professionals and researchers in the future.
For this study, 300 male and female participants aged 18 and older will be recruited at approximately 40 sites.
You are about to start taking edaravone per your standard of care treatment for your ALS treatment. We will ensure that your visits for the clinical trial are scheduled around your standard of care treatment.
UPCOMING TRIALS
Darifenacin
A randomized, double-blind, placebo-controlled, single center, trial to test the safety, tolerability, pharmacokinetics and pharmacodynamics of Darifenacin in adults with ALS
The research builds on previous research showing that loss of nerve supply, or denervation, of neuromuscular junctions is one of the earliest pathological events in ALS. The trial strategy is to target neuromuscular junctions to maintain this essential connection between neurons and muscles, thus improving muscle function, preventing muscle mass loss, and improving locomotion and survival.
In addition, the study will capture preliminary data on the effect of the therapeutic on function, and on muscle strength and integrity, to inform subsequent trial designs. Potential biomarkers will also be investigated.
Machine Learning in ALS
The purpose of this study is is to develop a tool that allows identification of UMN and LMN features in speech in patients with bulbar dysfunction due to ALS and other MND.
Learning more about characteristics of UMN and LMN symptoms in ALS/MND will help us to better understand the disease, possibly improve time between symptom onset and diagnosis and may result in new assessment and therapy tools.
For this study, 150 male and female participants will be recruited at about 11 ALS/MND clinics throughout Canada and the USA (in Toronto, London, Hamilton, Edmonton, Calgary, Saskatoon, Montreal, Quebec City, Fredericton, Gainesville and Ohio).
PROJENX PRO-101 (Prosetin)
A Phase 1C study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in ALS patients.
Prosetin is a selective, oral, brain-penetrant, MAP4K inhibitor developed by ProJenX co-founders at Columbia University for the treatment of ALS.
Following the discovery that MAP4K inhibition confers potent motor neuron protection across multiple patient stem cell-derived models of ALS, prosetin was optimized for potency against MAP4Ks, efficacy in motor neuron rescue, and preferential distribution to the CNS.
The Team – ALS
Dr Angela Genge
Principal Investigator
Dr Oliver Blanchard
Principal Investigator
Maria Gobbo
Clinical Research Coordinator
Maryam Leclerc
Clinical Research Coordinator
The Team – ALS
Dr Rami Massie
Principal Investigator
Vanessa Bertone
ALS Team Lead
Marie-Lise Béland
Clinical Research Coordinator
Lana McGeary
Research Coordinator
ACTIVE (NOT RECRUITING) TRIALS
AP101-02
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this project is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
Eligible participants will be randomized to take the study drug or a placebo by intravenous infusion (IV).
This study includes infusions at Day 1 and a maintenance dose at Day 2 and every 3 weeks until week 24. There is a follow-up after an additional 12 weeks.
Biogen 233AS102 (BIIB067)
From clinicaltrials.gov:
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 in participants with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation (SOD1-ALS). The secondary objective is to evaluate the pharmacokinetic (PK) profile of BIIB067 in participants with SOD1-ALS.
Biogen 275AS101 (Ataxin) (BIIB105)
The purpose of the study is to look at whether the BIIB105is safe and tolerable in people with ALS or polyQ-ALS. The study will also look at:
- What the body does to BIIB105(called “pharmacokinetics” or PK).
- The concentrations of BIIB105in the cerebrospinal fluid (CSF), which is the fluid around the spinal cord.
- What BIIB105does to the body (called “pharmacodynamics” or PD).
- Whether BIIB105affects the symptoms of ALS.
CALICO
ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is a 48-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be a 44-week active treatment extension (ATE) during which all subjects will receive ABBV-CLS-7262.
DAZALS
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)
The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Eligible ALS patients will be randomized to one of three treatment arms (1:1:1) across North America and Europe for a 24-week double-blind treatment period.
Patients who complete participation (i.e., completed all visits) in the double-blind treatment period will be eligible for participation in a 132-week open-label extension (OLE) study. A daily dose of 300 mg dazucorilant will be used in the 132-week OLE period.
Patients that complete the double-blind treatment period and who do not enter the OLE will enter the 132-week follow-up period.
HIMALAYA (ACT16970 - SAR443820)
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis
This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an open label, longterm extension period.
Study ACT16970 consists of 2 parts (A and B) as follows:
Part A is a 24week, double blind, placebo controlled part, preceded by a screening period of up to 4 weeks before Day 1.
Part B is an open label, longterm extension period that starts from the end of Part A (Week 24) and continues up to Week 106.
VERGE Genomics
A study to assess the safety and tolerability of escalating doses of VRG50635, a small molecule inhibitor of PIKfyve, a therapeutic target for ALS
SPOTLIGHT ON OUR RESEARCH
Click to read